NDAORALTABLETPriority Review
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
VERZENIO (abemaciclib) by Eli Lilly and Company is kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2017.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERZENIO (abemaciclib) is an oral small-molecule cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved by the FDA in September 2017. It is used to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer in combination with endocrine therapy. The drug works by inhibiting CDK4/6 proteins that drive cell cycle progression in cancer cells.
$757MPart D
Peak5.0 years to LOEVERZENIO is at peak sales with strong Part D utilization, indicating a mature, well-established franchise requiring sustained commercial and medical support teams.
Mechanism of Action
Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of Abemaciclib (LY2835219) in Healthy Participants
Started Sep 2026
15 enrolled
Healthy Volunteers
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Started Oct 2025
285 enrolled
Breast Cancer
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Started Mar 2025
191 enrolled
Non Small Cell Lung CancerGlioma Glioblastoma MultiformeGlioma, Malignant+4 more
Abemaciclib in Newly Diagnosed Meningioma Patients
Started Mar 2025
72 enrolled
Meningioma
A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
Started Mar 2025
18 enrolled
Retroperitoneal SarcomaLiposarcomaDedifferentiated Liposarcoma
Worked on VERZENIO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.